Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.41 |
| ▸ | SRC | P12931 | 8/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052736 | 1.00 | TACR1 (0.41) | TACR1SRCNR1H2DPP4MEN1 | |
| SCHEMBL20005803 | 1.00 | TACR1 (0.41) | TACR1SRCNR1H2DPP4MEN1 | |
| SCHEMBL19995973 | 1.00 | TACR1 (0.41) | TACR1SRCNR1H2DPP4MEN1 | |
| SCHEMBL21136410 | 1.00 | TACR1 (0.41) | TACR1SRCNR1H2DPP4MEN1 | |
| SCHEMBL29035191 | 0.88 | TACR1 (0.50) | TACR1SRCNR1H2 | |
| SCHEMBL29523555 | 0.88 | TACR1 (0.50) | TACR1SRCNR1H2 | |
| SCHEMBL29035189 | 0.88 | TACR1 (0.50) | TACR1SRCNR1H2 | |
| SCHEMBL29035386 | 0.88 | TACR1 (0.50) | TACR1SRCNR1H2 | |
| SCHEMBL29523008 | 0.88 | TACR1 (0.50) | TACR1SRCNR1H2 | |
| SCHEMBL23454767 | 0.83 | CYP1A2 (0.38) | TACR1NR1H2DPP4CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL PORTELA & CA SA (PT) | 2023-05-04 | — | — | US | disclosed |
| US-11434242-B2 | Dopamine-b-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2022-09-06 | — | — | US | disclosed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | TACR1 208/4885SRC 4427/4885NR1H2 355/4885 |
| US-11434242-B2 | Dopamine-b-hydroxylase inhibitors | DBH, MAOB, COMT | TACR1 194/4885SRC 4331/4885NR1H2 572/4885 |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | TACR1 189/4885SRC 4525/4885NR1H2 384/4885 |
| US-20230138795-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | TACR1 130/4885SRC 4275/4885NR1H2 798/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | TACR1 205/4885SRC 4399/4885NR1H2 343/4885 |
| US-20210171528-A1 | DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, MAOB, COMT | TACR1 194/4885SRC 4331/4885NR1H2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.